Gain Therapeutics Inc (GANX)

05:05 AM

Gain Therapeutics, Inc Hosts Key Opinion Leader Event on GT-02287 - TradingView

05:05 AM

02:55 AM

Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at HC Wainwright - Defense World

02:55 AM

02:52 AM

How risky is Gain Therapeutics Inc. stock nowJuly 2025 Patterns & Entry and Exit Point Strategies - newser.com

02:52 AM

05:24 AM

Intraday pattern recognizer results for Gain Therapeutics Inc.Weekly Trend Report & Risk Controlled Daily Trade Plans - newser.com

05:24 AM

05:23 AM

Institutional scanner results for Gain Therapeutics Inc.Earnings Beat & Accurate Technical Buy Alerts - newser.com

05:23 AM

Oct 13, 2025

Certain Options of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener

Oct 13, 2025

Oct 13, 2025

Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025. - MarketScreener

Oct 13, 2025

Oct 13, 2025

Is Gain Therapeutics Inc. still worth holding after the dip2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com

Oct 13, 2025

Oct 13, 2025

Will Gain Therapeutics Inc. stock benefit from sector rotationEarnings Trend Report & Weekly High Return Forecasts - newser.com

Oct 13, 2025

Oct 13, 2025

How to build a dashboard for Gain Therapeutics Inc. stockJuly 2025 Fed Impact & Advanced Technical Analysis Signals - newser.com

Oct 13, 2025

Oct 13, 2025

Is Gain Therapeutics Inc. stock entering bullish territory2025 Historical Comparison & Smart Investment Allocation Tips - newser.com

Oct 13, 2025

Oct 13, 2025

HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy Recommendation - Nasdaq

Oct 13, 2025

Oct 12, 2025

What does recent volatility data suggest for Gain Therapeutics Inc.Earnings Miss & High Return Trade Opportunity Guides - newser.com

Oct 12, 2025

Oct 10, 2025

How to forecast Gain Therapeutics Inc. trends using time seriesTrade Volume Report & Reliable Intraday Trade Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Published on: 2025-10-10 04:06:35 - newser.com

Oct 10, 2025

Oct 09, 2025

Eric Richman Resigns from Gain Therapeutics Board - TipRanks

Oct 09, 2025

Oct 09, 2025

Allosteric small molecule therapies in PD, with Gene Mack - pharmaphorum

Oct 09, 2025

Oct 09, 2025

Is Gain Therapeutics Inc. stock cheap at current valuationBreakout Watch & Daily Stock Trend Watchlist - newser.com

Oct 09, 2025

Oct 09, 2025

Is it time to cut losses on Gain Therapeutics Inc.2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com

Oct 09, 2025

Oct 09, 2025

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - The Manila Times

Oct 09, 2025

Oct 09, 2025

Gain Therapeutics to Host Virtual KOL Event on GT-02287 and Parkinson's Disease Research - Quiver Quantitative

Oct 09, 2025

Oct 09, 2025

Applying big data sentiment scoring on Gain Therapeutics Inc.Weekly Gains Report & AI Driven Price Forecasts - newser.com

Oct 09, 2025

Oct 09, 2025

Gain Therapeutics (NASDAQ:GANX) Given Sell (E+) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 08, 2025

Gain Therapeutics Supports Reliable Data Management In Labs - Kalkine Media

Oct 08, 2025

Oct 08, 2025

Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World

Oct 08, 2025

Oct 07, 2025

Is Gain Therapeutics Inc a good long term investmentVolume Spike Alerts & Small Budget Big Profits - earlytimes.in

Oct 07, 2025

Oct 07, 2025

Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq

Oct 07, 2025

Oct 07, 2025

Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus

Oct 07, 2025

Oct 06, 2025

Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com

Oct 06, 2025

Oct 06, 2025

Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat

Oct 06, 2025

Oct 06, 2025

Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com

Oct 06, 2025

Oct 06, 2025

Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia

Oct 06, 2025

Oct 06, 2025

Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative

Oct 06, 2025

Oct 06, 2025

Gain Therapeutics' GT-02287 Shows UPDRS Improvement in 9 by Day 90 | GANX Stock News - Stock Titan

Oct 06, 2025

Oct 06, 2025

What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com

Oct 06, 2025

Oct 06, 2025

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat

Oct 06, 2025

Oct 06, 2025

Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com

Oct 06, 2025

Oct 06, 2025

Does Gain Therapeutics Inc. stock trade at a discount to peers2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com

Oct 06, 2025

Oct 06, 2025

Gain Therapeutics (NASDAQ:GANX) versus Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head Review - Defense World

Oct 06, 2025

Oct 05, 2025

What moving averages say about Gain Therapeutics Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com

Oct 05, 2025

Oct 05, 2025

Applying Wyckoff theory to Gain Therapeutics Inc. stockWall Street Watch & Free Community Supported Trade Ideas - newser.com

Oct 05, 2025

Oct 03, 2025

Analyzing drawdowns of Gain Therapeutics Inc. with statistical tools2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com

Oct 03, 2025